Company Overview of Moderna Therapeutics, Inc.
Moderna Therapeutics, Inc. develops messenger RNA therapeutics. The company provides in vivo drug modality that produces human proteins or antibodies inside patient cells. It also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. The company focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology. Moderna Therapeutics, Inc. has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals, Inc. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.
200 Tech Square
Cambridge, MA 02139
Founded in 2009
Key Executives for Moderna Therapeutics, Inc.
Founding Chief Executive Officer
President of Research and Development
Senior Vice President of Technology Strategy
Compensation as of Fiscal Year 2014.
Moderna Therapeutics, Inc. Key Developments
Moderna Therapeutics Appoints Stephen Kelsey as President of Onkaido
Jul 1 14
Moderna Therapeutics announced that Stephen Kelsey, M.D., will become president of Onkaido Therapeutics, Moderna's oncology drug development company, effective July 21, 2014. Launched in January of this year, Onkaido is Moderna's first venture company, focused exclusively on developing and commercializing mRNA-based oncology treatments. Most recently Dr. Kelsey was senior vice president, new projects at the cancer therapies company Medivation. Dr. Kelsey graduated with a Doctorate of Medicine from the University of Birmingham, UK and is a fellow of both the Royal Colleges of Physicians and Pathologists, UK.
Moderna Announces Expansion to New Facility in Kendall Square
Jun 12 14
Moderna Therapeutics announced the company's expansion to 320 Bent Street in the Kendall Square area of Cambridge, a move that adds nearly 50,000 square feet of office, laboratory and manufacturing facilities to Moderna's operations in Massachusetts. The new site at 320 Bent Street will house Moderna Venture Incubator laboratories, non-GMP production facilities, and the relocated offices of Moderna's headquarters. The company's former headquarters at 200 Technology Square in Cambridge will remain occupied by Moderna and be dedicated to research and development and GMP manufacturing.
Moderna Therapeutics Announces Formation of Technology Advisory Board
May 21 14
Moderna Therapeutics announced the formation of a Technology Advisory Board. This new Technology Advisory Board will bring together a world-class panel of experts to advise Moderna on building GMP (Good Manufacturing Practice) manufacturing capabilities to deliver high-quality mRNA Active Pharmaceutical Ingredient (API) for its own clinical programs, and for organizations with which Moderna has strategic agreements. These include AstraZeneca, Alexion Pharmaceuticals and DARPA (the Defense Advanced Research Projects Agency).
The Board will focus initially on scaling the production of mRNA from micrograms to kilograms to full commercial scale, and on ensuring the use of best-in-class purification techniques and analytical tools. The members of the Technology Advisory Board are: Dr. Noubar Afeyan, Ph.D., co-founder and chairman of Moderna, managing partner and CEO of Flagship Ventures, founder and CEO of PerSeptive Biosystems. Dr. John Aunins, Ph.D., executive vice president, CMC, of Seres Health, Inc., former VP of process development at Merck Inc. Dr. Scott Canute, former president of manufacturing at Genzyme, former president of manufacturing at Eli Lilly. Professor Fred Regnier, Ph.D., J.H. Law distinguished professor of chemistry at Purdue University. Professor James Swartz, Ph.D., professor of chemical engineering at Stanford University, former engineer at Genentech and Eli Lilly. Professor Jack Szostak, Ph.D., Nobel Prize in Medicine 2009, Howard Hughes medical institute investigator, professor of genetics at Harvard Medical School, and Alex Rich distinguished investigator, Dept. of Molecular Biology and the Center for Computational and Integrative Biology at Massachusetts General Hospital. Professor Richard Willson, Ph.D., Huffington-Woestemeyer professor in chemical and biomolecular engineering at the University of Houston.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 13, 2014
November 6, 2013